NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT
Post# of 169
(Total Views: 225)
Posted On: 08/11/2023 4:29:37 PM
NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2023 Financial Report, Corporate Update
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, is reporting its financial and operational results for the second quarter ended June 30, 2023. Highlights of the report include the closing of a $25 million secondary offering and $1.5 million registered direct offering, resulting in gross proceeds for HeartBeam of $26.5 million; the announcement in the “Journal of American College of Cardiology: Advances” of a foundational study evaluating the ability of the company’s VECG technology platform to detect the presence of coronary artery occlusions; the addition of three members to the company’s board of directors along with the announcement of Deborah Castillo, PhD, as VP of regulatory affairs; receiving an automated cardiac detection patent from the United States Patent and Trademark Office for the AIMIGo(TM) System; and the submission of a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for version 1 of the HeartBeam AIMIGo System.
“The second quarter of 2023 was highlighted by continued progress and validation of our technologies, the publication of our first, and foundational, study demonstrating the ability of our VECG platform, and several key additions to the team,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Our strategic focus is to enable timely delivery of our ambulatory VECG products, which are our key future value drivers. . . . We recently closed $26.5 million in common stock-only financings to fund operations into late 2024. Proceeds are being used to fund development and regulatory work for the HeartBeam AIMIGo VECG device and to ready the product for limited market release during the second half of 2024. The product and regulatory efforts include first obtaining an FDA 510(k) clearance for the HeartBeam AIMIGo VECG device. We submitted this application to the FDA in May. This will be followed by a second FDA application on the system’s ability to synthesize a 12L ECG. We look forward to providing updates on our progress in the months ahead.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, is reporting its financial and operational results for the second quarter ended June 30, 2023. Highlights of the report include the closing of a $25 million secondary offering and $1.5 million registered direct offering, resulting in gross proceeds for HeartBeam of $26.5 million; the announcement in the “Journal of American College of Cardiology: Advances” of a foundational study evaluating the ability of the company’s VECG technology platform to detect the presence of coronary artery occlusions; the addition of three members to the company’s board of directors along with the announcement of Deborah Castillo, PhD, as VP of regulatory affairs; receiving an automated cardiac detection patent from the United States Patent and Trademark Office for the AIMIGo(TM) System; and the submission of a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for version 1 of the HeartBeam AIMIGo System.
“The second quarter of 2023 was highlighted by continued progress and validation of our technologies, the publication of our first, and foundational, study demonstrating the ability of our VECG platform, and several key additions to the team,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Our strategic focus is to enable timely delivery of our ambulatory VECG products, which are our key future value drivers. . . . We recently closed $26.5 million in common stock-only financings to fund operations into late 2024. Proceeds are being used to fund development and regulatory work for the HeartBeam AIMIGo VECG device and to ready the product for limited market release during the second half of 2024. The product and regulatory efforts include first obtaining an FDA 510(k) clearance for the HeartBeam AIMIGo VECG device. We submitted this application to the FDA in May. This will be followed by a second FDA application on the system’s ability to synthesize a 12L ECG. We look forward to providing updates on our progress in the months ahead.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)